第8巻 2012年4月　第2号

■臨床および実験報告

80歳以上の高齢者進行食道癌に対するDocetaxel/Nedaplatin/5-FU併用化学放射線療法
松谷　毅¹, 野村　務¹, 萩原　信敏¹, 吉田　寛^1,2, 宮下　正夫¹, 内田　英二^1
1日本医科大学大学院医学研究科臓器病態制御外科学
²日本医科大学多摩永山病院外科

Chemoradiation Therapy with Docetaxel/Nedaplatin and Fluorouracil for Patients Older than 80 Years with Advanced Esophageal Cancer
Takeshi Matsutani¹, Tsutomu Nomura¹, Nobutoshi Hagiwara¹, Hiroshi Yoshida^1,2, Masao Miyashita¹ and Eiji Uchida^1
1)Surgery for Organ Function and Biological Regulation, Graduate School of Medicine, Nippon Medical School
²⁾Department of Surgery, Nippon Medical School Tama Nagayama Hospital

The purpose of this study was to evaluate the safety and efficacy of chemoradiation therapy with docetaxel, nedaplatin and fluorouracil (5-FU) for patients older than 80 years with advanced esophageal cancer. Three patients were enrolled and received the combination of docetaxel (30 mg/m² on day 1), nedaplatin (10 mg/body on days 1∼5), and 5-FU (250 mg/m² on days 1∼5) with radiation (50.4 to 60 Gy in 1.8 to 2-Gy fractions over 6 weeks). Macroscopic and pathologic examinations after treatment showed no esophageal cancers; therefore complete responses were achieved in all patients, and the overall response rate was 100%. Myelosuppressions with grade 2 leukopenia occurred in 2 patients (66%), and grade 3 leukopenia occurred in 1 patient (33%). This chemoradiation therapy is effective and well tolerated by patients older than 80 years with advanced esophageal cancer.

日医大医会誌 2012; 8(2), 143-146

Key words
esophageal carcinoma, elderly patient, chemoradiation therapy

Correspondence to
Takeshi Matsutani, Department of Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
E-mail：matsutani@nms.ac.jp

受付：2011年11月25日　受理：2012年1月6日